-+ 0.00%
-+ 0.00%
-+ 0.00%

Things Look Grim For NeuroPace, Inc. (NASDAQ:NPCE) After Today's Downgrade

Simply Wall St·11/16/2026 10:27:48
Listen to the news

One thing we could say about the analysts on NeuroPace, Inc. (NASDAQ:NPCE) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business.

Following the downgrade, the latest consensus from NeuroPace's ten analysts is for revenues of US$109m in 2027, which would reflect a reasonable 2.4% improvement in sales compared to the last 12 months. Losses are expected to increase slightly, to US$0.44 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$122m and losses of US$0.26 per share in 2027. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

Check out our latest analysis for NeuroPace

earnings-and-revenue-growth
NasdaqGM:NPCE Earnings and Revenue Growth November 16th 2026

The consensus price target fell 29% to US$14.11, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that NeuroPace's revenue growth is expected to slow, with the forecast 1.9% annualised growth rate until the end of 2027 being well below the historical 20% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 7.5% annually. Factoring in the forecast slowdown in growth, it seems obvious that NeuroPace is also expected to grow slower than other industry participants.

The Bottom Line

The most important thing to take away is that analysts increased their loss per share estimates for next year. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that NeuroPace's revenues are expected to grow slower than the wider market. With a serious cut to next year's expectations and a falling price target, we wouldn't be surprised if investors were becoming wary of NeuroPace.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple NeuroPace analysts - going out to 2028, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.